- Co-Diagnostics (NASDAQ:CODX): Q3 GAAP EPS of -$0.10 misses by $0.04.
- Revenue of $0.04M (+300.0% Y/Y) misses by $0.78M.
- Press Release
- More news on: Co-Diagnostics, Inc., Earnings news and commentary, Healthcare stocks news, ,
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address PR Newswire Presentation included announcement of the opening of the new manufacturing facility in Salt Lake City, UT SALT LAKE CITY , March 21, 202...
Co-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, England PR Newswire SALT LAKE CITY, Utah , March 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company...
Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results PR Newswire SALT LAKE CITY , March 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagno...